, with SES denotes standardized effect size. A relative efficiency >1 suggested that the domain was more efficient than the tender joint count in detecting the observed treatment effect. RESULTS: At 6 months, the mHAQ summary score improved 42% for the CTLA4Ig 10 mg/kg group compared to 14% for the placebo group. This improvement was considered to be clinically meaningful based on the commonly accepted threshold. Patients in the 10 mg/kg group also experienced statistically significant improvements compared to the placebo group in the following domains: eating (32% more improvement), hygiene (32% more), grip (24% more), dressing (20% more), and walking (16% more). Moreover, these physical domains were shown to be as responsive as the tender joint count to detect a treatment effect, with relative efficiencies close to one. CONCLU-SIONS: treatment with CTLA4Ig significantly improved physical function in patients with active RA, especially in areas related to eating, hygiene, grip, and walking ability. Measures in physical function are efficient in detecting clinical improvements important to patients. 
QL3

DIABETIC PATIENTS' WILLINGNESS TO PAY FOR DIABETES EDUCATION BY PHARMACISTS: VALIDITY OF CONTINGENT VALUATION METHOD
OBJECTIVES:
This study was conducted to measure diabetic patients' willingness-to-pay (WTP) for diabetes education provided by pharmacists utilizing the contingent valuation method, to determine factors which influence patients' WTP, and to test starting point bias and scope effects. METHODS: Diabetic patients, randomly selected at 2 hospital endocrinology clinics, were interviewed to measure their WTP for education resulting in 3 hypothetical risk-reductions in diabetic complications (reduction from 75% without education to 37.5% with education, 50%®25%, and 25%®12.5%) using a bidding game with randomly assigned starting amounts ($10/$40). Sample mean (SM) and mean based on lognormal distribution (LNM) were calculated. Mean WTP was calculated using 2-part model (PM) with a smear estimator, and Heckman 2-stage model (HM) for sample selection correction, which were further used to determine significant factors influencing WTP amount.
RESULTS:
A total of 283 patients were interviewed. Patients' mean age and household income was 53.5 years and $60,202 respectively. In total, 59% of patients were willing-to-pay. SMs were $36 ± $49 for 75%AE37.5%; $35 ± $50 for 50%AE25%; and $26 ± $42 for 25%AE12.5%. SMs were similar to LNMs. Means based on HM were $41 ± $23 for the 75%AE37.5%, $38 ± $19 for 50%AE25%; and $27 ± $16 for 25%AE12.5%, which were nearly the same as means calculated based on PM. In HM model, patients were willing-to-pay significantly larger amounts as risk-reduction level increased (P < 0.001), as starting amount increased (P < 0.001), and if neuropathy was present (P < 0.001 
